Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | NQO2 | P16083 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8088647 | 1.00 | POLB (0.60) | POLBMEN1KMT2ANQO2MTNR1A | |
| SCHEMBL8101590 | 0.94 | POLB (0.59) | POLBMEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL3578970 | 0.94 | POLB (0.59) | POLBMEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL25592977 | 0.91 | MEN1 (0.65) | POLBMEN1KMT2ANQO2MTNR1A | |
| SCHEMBL3576515 | 0.84 | MEN1 (0.55) | POLBMEN1KMT2ANQO2MTNR1A | |
| SCHEMBL3583135 | 0.84 | POLB (0.56) | POLBMEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL8097313 | 0.84 | POLB (0.56) | POLBMEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL25592921 | 0.81 | CYP3A4 (0.66) | POLBMEN1KMT2AATMALDH1A1 | |
| SCHEMBL3572040 | 0.81 | POLB (0.70) | POLBMEN1KMT2AATMALDH1A1 | |
| SCHEMBL3573621 | 0.78 | FKBP1A (0.68) | POLBMEN1KMT2AATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130028843-A1 | KALLIKREIN 7 MODULATORS | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | disclosed |
| US-8309596-B2 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2012-11-13 | — | — | US | disclosed |
| US-20100256144-A1 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028843-A1 | KALLIKREIN 7 MODULATORS | KLK7, KLK5, KLKB1 | POLB 4716/4885MEN1 921/4885KMT2A 1804/4885 |
| US-20100256144-A1 | Kallikrein 7 modulators | KLK7, KLK5, KLKB1 | POLB 4716/4885MEN1 921/4885KMT2A 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.